Sep 12, 2022 / 08:30PM GMT
Boobalan Pachaiyappan - H.C. Wainwright & Co. - Analyst
Hello, everyone. My name is Boobalan Pachaiyappan. I'm Vice President and Senior Analyst at H.C. Wainwright. With me today is Dr. Mel Sorensen, Chief Executive Officer and President of Galera Therapeutics. Mel, welcome to the show.
Mel Sorensen - Galera Therapeutics, Inc. - President & CEO
Good to be here.
Boobalan Pachaiyappan - H.C. Wainwright & Co. - Analyst
Great. So, before we get started, I just wanted to make a disclosure here. We cover Galera Therapeutics. And I covered with my colleague, Dr. Ram Selvaraju, who is the Managing Director and Senior Analyst at the firm. Our recommendation for the stock is by rating and a $10 price target. I'm sure some are new to the Galera story. Maybe I'll just provide a little bit of background before we get to the meat of the story.
So, Galera is focused on developing small molecule treatments to transform the radiotherapy space. They have a flagship asset, which is Avasopasem. It produced positive
Galera Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers